{"id":"https://openalex.org/W2171751908","doi":"https://doi.org/10.1200/jco.2006.09.5125","title":"Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study","display_name":"Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study","publication_year":2007,"publication_date":"2007-04-18","ids":{"openalex":"https://openalex.org/W2171751908","doi":"https://doi.org/10.1200/jco.2006.09.5125","mag":"2171751908","pmid":"https://pubmed.ncbi.nlm.nih.gov/17442993"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.09.5125","doi":"https://doi.org/10.1200/jco.2006.09.5125","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.09.5125","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028056789","display_name":"Susan R. Rheingold","orcid":"https://orcid.org/0000-0001-8025-6767","observed_orcids":["https://orcid.org/0000-0001-8025-6767"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan R. Rheingold","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045426069","display_name":"Michael D. Hogarty","orcid":"https://orcid.org/0000-0002-9221-4852","observed_orcids":["https://orcid.org/0000-0002-9221-4852"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael D. Hogarty","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027468886","display_name":"Susan M. Blaney","orcid":"https://orcid.org/0000-0002-6194-4799","observed_orcids":["https://orcid.org/0000-0002-6194-4799"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan M. Blaney","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033174879","display_name":"James A. Zwiebel","orcid":"https://orcid.org/0000-0003-4455-8789","observed_orcids":["https://orcid.org/0000-0003-4455-8789"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James A. Zwiebel","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050680216","display_name":"Calies Sauk-Schubert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Calies Sauk-Schubert","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091515106","display_name":"Reddy Chandula","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reddy Chandula","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090325707","display_name":"Mark Krailo","orcid":"https://orcid.org/0000-0002-7608-0698","observed_orcids":["https://orcid.org/0000-0002-7608-0698"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark D. Krailo","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066484657","display_name":"Peter C. Adamson","orcid":"https://orcid.org/0000-0002-9487-757X","observed_orcids":["https://orcid.org/0000-0002-9487-757X"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]},{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter C. Adamson","raw_affiliation_strings":["From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Children's Hospital of Philadelphia, Philadelphia, PA; Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX; Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD; Genta Inc, Berkeley Heights, NJ; Children's Oncology Group, Arcadia; and University of Southern California Keck School of Medicine, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I1335321130","https://openalex.org/I181547552"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.8527,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.85026605,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"25","issue":"12","first_page":"1512","last_page":"1518"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.1599999964237213,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.1599999964237213,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.10970000177621841,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.07000000029802322,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/g3139","display_name":"G3139","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bcl-2-antisense-oligonucleotide","display_name":"Bcl-2 antisense oligonucleotide","score":0.9710000157356262},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9039999842643738},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":1.0},{"id":"https://openalex.org/keywords/relapsed-solid-tumors","display_name":"relapsed solid tumors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/pediatric-oncology","display_name":"pediatric oncology","score":0.8140000104904175},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8690000176429749},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8220000267028809},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8050000071525574},{"id":"https://openalex.org/keywords/bcl-2-expression","display_name":"Bcl-2 expression","score":0.9480000138282776},{"id":"https://openalex.org/keywords/continuous-infusion","display_name":"continuous infusion","score":0.6159999966621399},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.796165406703949},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7946127653121948},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.7423843145370483},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.6651180982589722},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.637521505355835},{"id":"https://openalex.org/C2779720357","wikidata":"https://www.wikidata.org/wiki/Q524995","display_name":"Dexrazoxane","level":5,"score":0.5589284896850586},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5493112802505493},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5487990975379944},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.48209765553474426},{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.43890732526779175},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4376927614212036},{"id":"https://openalex.org/C2778670039","wikidata":"https://www.wikidata.org/wiki/Q414004","display_name":"Nitrogen mustard","level":4,"score":0.4228050708770752},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.41324174404144287},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40685713291168213},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.39796721935272217},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3808738589286804},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.2782336473464966},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2585142254829407},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.12905466556549072},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.08444929122924805}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006776","descriptor_name":"Hospitals, Pediatric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007223","descriptor_name":"Infant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008495","descriptor_name":"Medical Oncology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013873","descriptor_name":"Thionucleotides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013873","descriptor_name":"Thionucleotides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1200/jco.2006.09.5125","doi":"https://doi.org/10.1200/jco.2006.09.5125","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.09.5125","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:17442993","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17442993","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.988.6616","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.988.6616","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://hwmaint.jco.ascopubs.org/cgi/reprint/25/12/1512.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6600000262260437,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G5524335007","display_name":"General Clinical Research Center","funder_award_id":"M01RR002172","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G5918705860","display_name":"General Clinical Research Center","funder_award_id":"M01RR000585","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G6953653749","display_name":"General Clinical Research Center","funder_award_id":"M01RR000037","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G7057538999","display_name":"General Clinical Research Center","funder_award_id":"M01RR000188","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G7088267319","display_name":"Children's Oncology Group Phase 1 / Pilot Consortium","funder_award_id":"U01CA097452","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8352170253","display_name":"General Clinical Research Center","funder_award_id":"M01RR000084","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W131994123","https://openalex.org/W154264227","https://openalex.org/W206855962","https://openalex.org/W1501414399","https://openalex.org/W1580368676","https://openalex.org/W1585081258","https://openalex.org/W1911252495","https://openalex.org/W1963571549","https://openalex.org/W1992844265","https://openalex.org/W2021817265","https://openalex.org/W2046880698","https://openalex.org/W2055298098","https://openalex.org/W2064641151","https://openalex.org/W2096030635","https://openalex.org/W2100888471","https://openalex.org/W2101617519","https://openalex.org/W2107210199","https://openalex.org/W2113211717","https://openalex.org/W2128559106","https://openalex.org/W2129683520","https://openalex.org/W2130115789","https://openalex.org/W2134952321","https://openalex.org/W2136966358","https://openalex.org/W2139248078","https://openalex.org/W2161948946","https://openalex.org/W2167478584","https://openalex.org/W2171342364","https://openalex.org/W2171351296","https://openalex.org/W2182825613","https://openalex.org/W2208136208","https://openalex.org/W2259568108","https://openalex.org/W2290539832","https://openalex.org/W2403312794","https://openalex.org/W2471500742"],"related_works":["https://openalex.org/W2223043595","https://openalex.org/W2265951629","https://openalex.org/W2121896572","https://openalex.org/W2248180091","https://openalex.org/W2167478584","https://openalex.org/W2110003494","https://openalex.org/W2417979235","https://openalex.org/W2094042165","https://openalex.org/W2106489628","https://openalex.org/W2257426985"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"determine":[2],"the":[3,57,66,121,135,154,186,244],"maximum-tolerated":[4],"dose,":[5,153],"toxicity,":[6],"pharmacokinetics,":[7],"and":[8,17,47,54,60,109,194,229,236,249],"biologic":[9,171,253],"effects":[10,246,254],"of":[11,34,40,56,83,92,96,123,142,174,191,197,215,247,255],"G3139":[12,41,160,192,216,241,256],"when":[13],"administered":[14,50],"with":[15,21,120,170,200,225],"doxorubicin":[16,97,230,248],"cyclophosphamide":[18,110,226],"to":[19,78,131],"children":[20],"relapsed":[22],"solid":[23],"tumors.":[24],"PATIENTS":[25],"AND":[26],"METHODS:":[27],"Patients":[28],"received":[29],"a":[30,167,221],"7-day":[31,222],"continuous":[32,223],"infusion":[33],"3,":[35],"5,":[36],"or":[37],"7":[38,136,149,218],"mg/kg/d":[39,137,219],"every":[42],"21":[43],"days.":[44],"Doxorubicin,":[45],"cyclophosphamide,":[46],"dexrazoxane":[48,103],"were":[49,63,81,86,116],"on":[51,233],"days":[52,115,234],"5":[53,235],"6":[55],"infusion.":[58],"Pharmacokinetics":[59],"biology":[61],"studies":[62],"performed":[64],"during":[65],"first":[67,187],"course.":[68],"RESULTS:":[69],"Thirty-seven":[70],"patients,":[71],"median":[72],"age":[73],"14":[74,198],"years":[75],"(range,":[76],"1":[77,165],"19":[79],"years),":[80],"enrolled,":[82],"whom":[84],"29":[85],"fully":[87],"assessable":[88,188],"for":[89,100,106,113,252],"toxicity.":[90],"Because":[91],"dose-limiting":[93],"neutropenia,":[94],"doses":[95],"30":[98,231],"mg/m2/d":[99,105,112,228,232],"2":[101,107,114],"days,":[102,108],"300":[104],"500":[111,227],"reduced":[117,178],"initially,":[118],"but":[119],"addition":[122],"granulocyte":[124],"colony-stimulating":[125],"factor":[126],"(GCSF),":[127],"could":[128],"be":[129],"re-escalated":[130],"starting":[132],"doses.":[133],"At":[134,151],"dose":[138,214],"level,":[139],"only":[140],"one":[141],"six":[143],"patients":[144,176,199],"experienced":[145],"DLT":[146],"(neutropenia":[147],">":[148],"days).":[150],"this":[152,203],"average":[155],"(+/-":[156],"standard":[157],"deviation)":[158],"steady-state":[159],"concentration":[161,168],"was":[162,257],"2.04":[163],"+/-":[164],"microg/mL,":[166],"associated":[169],"activity.":[172],"Eleven":[173],"15":[175],"had":[177],"bcl-2":[179],"expression":[180],"in":[181,195],"peripheral-blood":[182],"mononuclear":[183],"cells":[184],"at":[185],"time":[189],"point":[190],"exposure,":[193],"eight":[196],"serial":[201],"specimens":[202],"reduction":[204],"persisted":[205],"through":[206],"day":[207],"6.":[208],"CONCLUSION:":[209],"The":[210],"recommended":[211],"phase":[212],"II":[213],"is":[217],"as":[220],"infusion,":[224],"6,":[237],"followed":[238],"by":[239],"GCSF.":[240],"may":[242],"accentuate":[243],"myelosuppressive":[245],"cyclophosphamide.":[250],"Evidence":[251],"demonstrated.":[258]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2016-06-24T00:00:00"}